Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*
British Journal of Dermatology2021Vol. 186(2), pp. 245–256
Citations Over TimeTop 10% of 2021 papers
Suzie Cro, Victoria Cornelius, Andrew Pink, Rebecca Wilson, Angela Pushpa‐Rajah, Prakash A. Patel, Alya Abdul‐Wahab, S. August, J. Azad, G Becher, Anna Chapman, Giles Dunnill, Adam Ferguson, A. Fogo, S.A. Ghaffar, John R Ingram, Svetlana Kavakleiva, E. Ladoyanni, Joyce Leman, A. E. Macbeth, Areti Makrygeorgou, Richard Parslew, Alan J. Ryan, Amit Sharma, Alexa R. Shipman, Catriona Sinclair, Rachel Wachsmuth, Richard Woolf, Andrew Wright, Helen McAteer, Juliet N. Barker, A. David Burden, C.E.M. Griffiths, Nick J. Reynolds, Richard B. Warren, Helen J. Lachmann, Francesca Capon, Catherine Smith, the APRICOT Study Group, Davide Altamura, Vincent Piguet, Roberto Verdolini, Marc Wallace, Kavitha Sundararaj, Nisha Arujuna, Charlotte Fleming, Ruth Lamb, J. H. Dodds, Sonia Baryschpolec, Hywel Cooper
Abstract
No evidence for the superiority of anakinra was found. IL-1 blockade is not a useful intervention for the treatment of PPP.
Related Papers
- → Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*(2021)31 cited
- → PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis(2016)14 cited
- → The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study(2022)2 cited
- W jaki sposób miarodajnie oceniać nasilenie łuszczycy(2016)
- 건선 환자에서 Cyclosporine 치료 효과와 관련된 인자에 대한 후향적 연구(2021)